Evaluation of surface contamination with cyclophosphamide following simulated hazardous drug preparation activities using two closed-system products

Abstract

Purpose. A preliminary investigation was conducted to evaluate and compare the effectiveness of two closed-system products in preventing contamination of typical pharmacy workplace surfaces with cyclophosphamide during simulated hazardous drug preparation activities in a controlled laboratory setting.

Methods. Two separate trials simulating hazardous drug compounding using cyclophosphamide were performed with two different closed-system products. Prior to each trial, work area surfaces of the biological safety cabinet (BSC) workbench, the BSC airfoil and front grill, and the floor below the BSC were cleaned, and wipe samples were collected and analyzed to determine, if present, levels of cyclophosphamide. Following each trial, wipe samples were collected from the work area surfaces to determine the hazardous drug containment effectiveness of each closed-system product.

Results. Cyclophosphamide was not detected on work area surfaces prior to each trial. Low levels were detected on the BSC workbench surface following both trials.

Discussion. Based on the limited number of samples obtained during this preliminary study and the determination of the presence of the chemical of interest on the drug vials, no statistical evaluation was performed to compare the relative effectiveness of the two systems tested. Work practices and procedures regarding product operation may affect hazardous drug containment and worker safety. Further study and statistical analyses are needed.

Keywords

Hazardous drug surface contamination effectiveness containment closed-system cyclophosphamide

References

World Health Organization (WHO). http://www.who.int/features/qa/15/en/index.html (accessed August 2009).

Connor TH and McDiarmid MA Preventing occupational exposures to antineoplastic drugs in health care settings . CA Cancer J Clin 2006; 56: 354-365.

American Society of Hospital Pharmacists. ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. Am J Hosp Pharm 1990; 47: 1033-1049.

Occupational Safety and Health Administration. ‘Categorization of drugs as hazardous’, Sec VI, Chapter II. OSHA Technical Manual, TED 1-0.15A, www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.html#2 (accessed August 2009).

National Institute for Occupational Safety and Health. NIOSH Alert: preventing occupational exposures to antineoplastic and other hazardous drugs in the health care setting. Centers for Disease Control and Prevention, National Institute for Occupation Safety and Health, DHHS (NIOSH) Publication No.2004-165. Washington, DC: U.S. Department of Health and Human Services.

The United States Pharmacopeial Convention. USP<797> Guidebook to pharmaceutical compounding - sterile preparations. In: The United States Pharmacopeial Convention, Rockville, MD, 2008.

Connor TH , Anderson RW , Sessink PJ and Spivey SM Effectiveness of a closed-system device in containing surface contamination with cyclophosphamide and ifosfamide in an i.v. admixture area. Am J Health-Syst Pharm 2002; 59: 68-72.

Harrison BR , Peters BG and Bing MR Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed-system drug transfer device versus standard preparation techniques . Am J Health-Syst Phar 2006; 63: 1736-1744.

Sessink PJM , Rolf ME and Ryden NS Evaluation of the PhaSeal® Hazardous Drug Containment System. Hosp Pharm 1999 ; 34: 1311-1317.

10.

Sessink PJM , Anzion RBM , van den Broek PHH , et al. Detection of contamination with antineoplastic agents in a hospital pharmacy department . Pharm World Sci 1992; 14: 16-22.

11.

Sessink PJM , Boer KA , Scheefhals APH , et al. Occupational exposure to antineoplastic agents at several departments in a hospital. Environmental contamination and excretion of cyclophosphamide and iphosfamide in urine of exposed workers . Int Arch Occup Environ Health 1992; 64: 105-112.

12.

Sessink PJM , Scholtes MM , Anzion RBM , et al. Determination of cyclophosphamide in urine by gas chromatography-mass spectrometry. J Chromatogr 1993; 616: 333-337.

13.

Sessink PJM. Monitoring of occupational exposure to antineoplastic agents, PhD Thesis, University Nijmegen.

14.

Connor TH , Anderson RW , Sessink PJ , Broadfield L. and Power LA Surface contamination with antineoplastic agents in six cancer treatment centers in Canada and the United States. Am J Health Syst Pharm 1999; 56: 1427-1432.

15.

Connor TH , Sessink PJ , Harrison BR , et al. Surface contamination of chemotherapy drug vials and evaluation of new vial-cleaning techniques: results of three studies. Am J Health-Syst Pharm 2005; 62: 475-484.

16.

Mason HJ , Morton J. , Garfitt SJ , et al. Cytotoxic drug contamination on the outside of vials delivered to a hospital pharmacy. Ann Occup Hy 2003; 47: 681-685.